Fecal Microbiota Transplantation for Eczema: A Nine-Completer Pilot, Later Trial and Infection Warnings
DOCTOR’S NOTES · ECZEMA EVIDENCE
Research on the gut–skin relationship has led to studies of fecal microbiota transplantation, or FMT, for eczema. That does not make donor-stool products interchangeable with ordinary dietary choices or probiotics. The study sequence, later evidence and known infection risks all matter before a favorable result is shared.
The early pilot used the same order for everyone
The 2022 primary pilot report describes adults receiving two placebo procedures, followed by four FMT procedures two weeks apart. Nine completed the protocol. At week 12, seven had at least 50% SCORAD improvement and four at least 75% improvement relative to the pre-FMT assessment.
| Design detail | Why it limits interpretation |
|---|---|
| Placebo always preceded active treatment | Treatment is entangled with time and sequence. |
| Nine protocol completers | Percentages represent very few individuals. |
| Two rapid relapses led to other treatment | Early response did not guarantee continuing control. |
| Additional FMT used for two exacerbations | Follow-up was not a simple fixed-course cure test. |
The fixed order is not the same as randomizing which treatment comes first. The absence of change during placebo is informative, but it cannot eliminate natural disease variation or every influence of elapsed time. No adverse events recorded in this small report does not establish general safety.
A later randomized trial is relevant, but the abstract has limits
Liu and colleagues’ randomized double-blind trial, online October 2024 and in the May 2025 issue, compared three weekly FMT or placebo administrations alongside standard background treatment. Its abstract reports greater EASI improvement and EASI-50 response with FMT and no serious adverse reactions. The accessible abstract does not provide the sample-size and exact effect estimates needed for a numerical benefit calculation, so none is invented here.
Do not erase the infection question
FDA’s March 2020 safety alert describes serious infections suspected to have been transmitted through investigational FMT products, including products obtained from prescreened donors. Those reports involved a different clinical setting, not the eczema trials. They nevertheless show why a small eczema study’s uneventful follow-up cannot establish that pathogen transmission is impossible.
Screening, preparation and medical oversight are central parts of this kind of intervention. A microbiome association is not a basis for home preparation or self-administration of donor material. Likewise, an increase in a microbial species after treatment does not by itself prove that species caused the clinical change.
Keep research participation separate from routine care
If considering an advertised microbiome service, ask who supervises it, whether it is a regulated research protocol for the exact condition, what safety protections apply and how complications are handled. Bring the study itself to the eczema clinician. Do not substitute a commercial promise for the care plan addressing current inflammation and symptoms.
For busy adults, follow-up burden and contingency plans matter as well as a response percentage. The early pilot, later controlled report and FDA safety information answer complementary questions; none justifies promising a permanent eczema cure.
Why evidence from one population cannot simply be transferred to another
Where moisture care fits
Dr. Arsy Moisturizer #003, 4 oz (120 g) is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. It does not treat, cure or prevent eczema and was not tested in the research discussed here. These findings do not establish pediatric efficacy or infant suitability for #003; ask a child’s clinician about an appropriate moisturizer.
Continue with a related question
- How to Read an Eczema Study Without Getting Misled by Percentages
- Your Eczema Itch Score and Your Rash Score Can Tell Different Stories
- What Is SCORAD? Understanding an Eczema Severity Score
Prepared by the Dr. Arsy editorial team. Sources checked November 9, 2026. Educational content does not diagnose an individual or imply independent medical review. Cited researchers and institutions do not endorse #003. Image is an AI-created editorial product illustration, not a patient photograph or clinical result.